Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (957)	6/26/2002 4:55:30 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1834

<<Dr. Tracy, Wouldn't a short-acting anxiolytic find a market for a short-duration anxiety episode, such as a panic attack? I'm a subscriber, so please don't land with both feet.>> 'Land with both feet'...I guess I am going to have to watch myself more carefully, if I have earned that reputation in the past.... The big challenge with GABA-A modulation has been one of separating out effects on specific subunits, in the hope of parsing effects: sedation vs. anxiolysis vs. cognition vs. anticonvulsant vs. motor impairment. If NBI-34060 is--and there is every evidence it is--an effective sedative hypnotic, if used as an anxiolytic, one would accept sedation as a side effect. That would run against the tide of anxiolytic research, which has been a search for a drug that reduces anxiety without sedative/cognitive side effects. I suppose one could argue that a short acting anxiolytic might be useful in panic--but then there is already Ativan. The better NBI-34060 is as a soporific, the less desirable a shortacting anxiolytic candidate it is. Though most panic patients would prefer to sleep through an attack rather than have to suffer through it. Harry Tracy NeuroInvestment www.neuroinvestment.com